Milbeguard Duo 16 mg / 40 mg film-coated tablets for cats

Authorised

- Milbemycin oxime
- Praziquantel

Product identification

Medicine name:
Milbeguard Duo 16 mg / 40 mg film-coated tablets for cats
Milbeguard Duo 16 mg/40 mg filmomhulde tabletten voor katten

Active substance:
Milbemycin oxime

Praziquantel

Target species:
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Milbemycin oxime
16.00 milligram(s) / 1.00 Tablet

Praziquantel
40.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Film-coated tablet

Withdrawal period by route of administration:

Oral use:

- **Cat**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AB51

Legal status of supply:
Veterinary medicinal product not subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Netherlands

Package description:
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 50 blisters of 2 tablets (100 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 24 blisters of 2 tablets (48 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 12 blisters of 2 tablets (24 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 5 blisters of 2 tablets (10 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 2 blisters of 2 tablets (4 tablets).
Polyamide-Aluminium-Polyvinyl chloride / aluminium heat sealed blisters: Cardboard box with 1 blister of 2 tablets (2 tablets).

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Ceva Sante Animale

Marketing authorisation date:
28/08/2023

Manufacturing sites for batch release:
Ceva Sante Animale

Responsible authority:
Medicines Evaluation Board

Authorisation number:
REG NL 130230

Date of authorisation status change:
6/02/2024

Reference member state:
Ireland

Procedure number:
IE/V/0780/005

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

Generic of:
600000004401

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.

Summary of Product Characteristics
